

Inmedix® CloudHRV® System surpasses 1000 procedures in its first 5 months

Soft launch of CloudHRV exceeds initial utilization and reimbursement expectations.

NORMANDY PARK, WA, UNITED STATES,
November 17, 2025 /

EINPresswire.com/ -- [Inmedix®](https://www.inmedix.com), Inc.

("Inmedix") announced today that its CloudHRV® System was used in patient care more than 1000 times in a soft launch among 5 clinics in WA, OR, MI and FL, exceeding utilization and payer reimbursement expectations. This is the first system cleared by the FDA as a

cloud-based, heart rate variability (HRV) diagnostic calculated from a high-fidelity 5-min electrocardiogram (ECG) which also includes Baevsky indices of parasympathetic and sympathetic activity. It represents a milestone in modern HRV assessment with scalability, precision and affordability for patients and clinicians in the clinical setting.

HRV provides indirect measures of the sympathetic (fight-or-flight) and parasympathetic (rest/restorative) components of the human autonomic nervous system (ANS). For medical grade HRV, a precision ECG is used to identify each heartbeat and to measure the precise timing between beats. These ECG measurements of heart rate (pulse) variability over time reflect how the autonomic nervous system (ANS) influences cardiac rhythm during respiration. Subsequently, mathematical formulae can be applied to render HRV indices of sympathetic and parasympathetic activity.

Inmedix CloudHRV provides comprehensive HRV at rest with medical precision in the clinic setting in just 5 minutes. Application of CloudHRV as a reimbursed tool for patient care is determined exclusively by the clinician and the CloudHRV ECG display is contraindicated for use to monitor or diagnose cardiovascular disease.

"The road can be arduous for meaningful innovation eventually cleared by the FDA," said Inmedix Co-founder, CEO and rheumatologist Andrew J Holman MD, "but that's now behind us.



Inmedix CloudHRV System

The subsequent soft launch this summer was designed to assess patient, clinic and doctor perspectives, Inmedix hardware and software support capabilities, and real-world utilization and reimbursement with detailed customer feedback.”

“As a clinical rheumatologist, I can appreciate the milestone of achieving over 1000 CloudHRV procedures completed in less than 5 months and among only 5 clinics. The Inmedix team did a fantastic job and the future of precision, FDA cleared HRV is getting truly exciting.”

About Inmedix, Inc. and its subsidiary, Inmedix UK, Ltd.

Seattle-based biotech/medtech Inmedix, Inc. and its subsidiary Inmedix UK, Ltd., are committed to engaging in world class research to discover innovative solutions for pressing healthcare needs related to the impact of stress modulated within the brain by the autonomic nervous system (ANS). Its CloudHRV System is FDA cleared to provide 1996 international standard time and frequency domain HRV as well as geometric domain HRV indices non-invasively in 5 minutes in the clinic setting.

NOTICE:

This Press Release contains certain forward-looking statements, including without limitation statements regarding Inmedix’s plans for preclinical studies, effectiveness of its research, product capabilities and the market’s demand for its respective products. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Inmedix’s business which could significantly affect expected results, including without limitation, progress of development, clinical testing, regulatory approval, developments in raw material, personnel costs, sales as well as legislative, fiscal, and other regulatory measures. Any forward-looking statements are qualified in their entirety by this cautionary statement, and Inmedix undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release. This is not an offer to sell or an offer to purchase securities.

Andrew J Holman MD

Inmedix Inc.

+1 206-466-3349

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/867783740>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.